BioSenic S.A.
BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Pha… Read more
BioSenic S.A. (BIOS) - Net Assets
Latest net assets as of June 2025: €-23.60 Million EUR
Based on the latest financial reports, BioSenic S.A. (BIOS) has net assets worth €-23.60 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€4.50 Million) and total liabilities (€28.10 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-23.60 Million |
| % of Total Assets | -524.47% |
| Annual Growth Rate | N/A |
| 5-Year Change | -906.29% |
| 10-Year Change | -195.25% |
| Growth Volatility | 4510.51 |
BioSenic S.A. - Net Assets Trend (2011–2024)
This chart illustrates how BioSenic S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BioSenic S.A. (2011–2024)
The table below shows the annual net assets of BioSenic S.A. from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-26.81 Million | -18.08% |
| 2023-12-31 | €-22.70 Million | -826.79% |
| 2022-12-31 | €3.12 Million | +146.18% |
| 2021-12-31 | €-6.76 Million | -303.46% |
| 2020-12-31 | €3.33 Million | +62.35% |
| 2019-12-31 | €2.05 Million | -54.40% |
| 2018-12-31 | €4.49 Million | +88.46% |
| 2017-12-31 | €2.38 Million | -84.39% |
| 2016-12-31 | €15.27 Million | -45.75% |
| 2015-12-31 | €28.15 Million | +396.75% |
| 2014-12-31 | €-9.48 Million | -15155.56% |
| 2013-12-31 | €63.00K | -97.61% |
| 2012-12-31 | €2.64 Million | -30.80% |
| 2011-12-31 | €3.81 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioSenic S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3149300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €8.57 Million | % |
| Other Comprehensive Income | €-74.00K | % |
| Other Components | €6.01 Million | % |
| Total Equity | €-25.07 Million | 100.00% |
BioSenic S.A. Competitors by Market Cap
The table below lists competitors of BioSenic S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
OPS Retail S.p.A.
F:DMM
|
$1.37 Million |
|
Odyssey Resources Limited
V:ODX-H
|
$1.37 Million |
|
USA Equities Corp
OTCQB:USAQ
|
$1.37 Million |
|
Atacama Resources International Inc
PINK:ACRL
|
$1.37 Million |
|
Orian Sh.M. Ltd
TA:ORIN
|
$1.37 Million |
|
NOVARTIS N - Dusseldorf Stock Exchang
DU:NOT
|
$1.37 Million |
|
MeaTech 3D Ltd
PINK:MTTCF
|
$1.37 Million |
|
Blende Silver Corp.
OTCQB:BAGGF
|
$1.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioSenic S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -22,912,000 to -25,074,000, a change of -2,162,000.
- Net loss of 4,768,000 reduced equity.
- Other comprehensive income decreased equity by 54,001.
- Other factors increased equity by 2,660,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-4.77 Million | -19.02% |
| Other Comprehensive Income | €-54.00K | -0.22% |
| Other Changes | €2.66 Million | +10.61% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares BioSenic S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | €0.76 | €0.00 | x |
| 2013-12-31 | €0.02 | €0.00 | x |
| 2014-12-31 | €-2.80 | €0.00 | x |
| 2015-12-31 | €4.26 | €0.00 | x |
| 2016-12-31 | €2.23 | €0.00 | x |
| 2017-12-31 | €0.35 | €0.00 | x |
| 2018-12-31 | €0.59 | €0.00 | x |
| 2019-12-31 | €0.21 | €0.00 | x |
| 2020-12-31 | €0.28 | €0.00 | x |
| 2021-12-31 | €-0.13 | €0.00 | x |
| 2022-12-31 | €0.03 | €0.00 | x |
| 2023-12-31 | €-0.17 | €0.00 | x |
| 2024-12-31 | €-0.11 | €0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioSenic S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-656.10%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -139.89% | 0.00% | 0.00x | 5.47x | €-3.95 Million |
| 2013 | -6474.60% | -403.46% | 0.08x | 203.35x | €-4.09 Million |
| 2014 | 0.00% | -475.85% | 0.05x | 0.00x | €-4.79 Million |
| 2015 | -50.25% | -831.51% | 0.03x | 1.79x | €-16.96 Million |
| 2016 | -85.06% | 0.00% | 0.00x | 2.53x | €-14.52 Million |
| 2017 | -535.12% | -31102.44% | 0.00x | 10.56x | €-12.99 Million |
| 2018 | -316.59% | -1421.80% | 0.04x | 5.73x | €-14.67 Million |
| 2019 | -510.79% | 0.00% | 0.00x | 10.93x | €-10.67 Million |
| 2020 | -359.10% | -1194.00% | 0.04x | 7.47x | €-12.27 Million |
| 2021 | 0.00% | -315.38% | 0.02x | 0.00x | €-717.00K |
| 2022 | -57.88% | -689.53% | 0.01x | 8.32x | €-2.39 Million |
| 2023 | 0.00% | -5299.82% | 0.06x | 0.00x | €-26.49 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | €-2.26 Million |
Industry Comparison
This section compares BioSenic S.A.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $115,519,167
- Average return on equity (ROE) among peers: -23.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioSenic S.A. (BIOS) | €-23.60 Million | -139.89% | N/A | $1.37 Million |
| EUROPEAN MEDICAL SOLUTIONS (ALEMS) | $9.89 Million | -7.17% | 3.42x | $49.45K |
| Celyad SA (CYAD) | $26.68 Million | -61.66% | 0.65x | $5.17 Million |
| Hyloris Developmentsen Sa (HYL) | $32.14 Million | -19.73% | 0.29x | $68.51 Million |
| Onward Medical N.V. (ONWD) | $-3.89 Million | 0.00% | 0.00x | $110.15 Million |
| Oxurion NV (OXUR) | $109.86 Million | -54.90% | 0.11x | $26.78K |
| Tubize-Fin (TUB) | $518.43 Million | 0.00% | 0.25x | $4.28 Billion |